The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection

This study has been completed.
Sponsor:
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00002347
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: June 1995

November 2, 1999
June 23, 2005
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00002347 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection
A Master Protocol to Evaluate the Safety and Efficacy of Multi-Drug Combination Antiretroviral Therapy for the Treatment of HIV Infection: Retrovir/HIVID/Nevirapine and Retrovir/HIVID/Invirase

To evaluate the tolerance and immunologic and virologic effects of multidrug combinations of antiretrovirals in patients with HIV infection. Specifically, to evaluate zidovudine/zalcitabine ( AZT / ddC ) alone or in combination with either nevirapine or saquinavir ( Ro 31-8959 ).

Administration of three-drug combinations for treatment of HIV infection is preferred over monotherapy or duotherapy. A system has been designed to rapidly evaluate current multidrug combinations of antiretrovirals and allow the addition of new agents as they become available.

Administration of three-drug combinations for treatment of HIV infection is preferred over monotherapy or duotherapy. A system has been designed to rapidly evaluate current multidrug combinations of antiretrovirals and allow the addition of new agents as they become available.

Patients are randomized to receive AZT/ddC either alone or in combination with nevirapine or Ro 31-8959 for a minimum of 48 weeks. Patients are followed at weeks 2 and 4 and every 4 weeks thereafter.

Interventional
Phase 2
Endpoint Classification: Efficacy Study
Masking: Double-Blind
Primary Purpose: Treatment
HIV Infections
  • Drug: Saquinavir
  • Drug: Nevirapine
  • Drug: Zidovudine
  • Drug: Zalcitabine
Not Provided
Thompson M, Myers M, Salgo M, Rousseau F, Odorisio M, Warburg M. A master protocol to evaluate the safety and efficacy of multidrug combination antiretroviral therapy with zidovudine and zalcitabine with or without saquinavir or nevirapine for the treatment of HIV infection. Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:109 (abstract no 242)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
225
Not Provided
Not Provided

Inclusion Criteria

Concurrent Medication:

Encouraged:

  • PCP chemoprophylaxis for patients whose CD4 count falls below 200 cells/mm3 or who develop PCP on study.

Allowed:

  • Secondary prophylaxis with nonexperimental agents in patients who develop TB, Mycobacterium avium-intracellulare, toxoplasmosis, histoplasmosis, cryptococcosis, disseminated candidiasis, or cytomegalovirus infection.
  • Acyclovir for 21 days or less for acute treatment.
  • Recombinant erythropoietin and G-CSF for grade 3 or worse anemia and neutropenia, respectively.

Patients must have:

  • HIV infection.
  • CD4 count 200 - 500 cells/mm3.
  • No prior antiretroviral therapy.
  • Life expectancy of at least 48 weeks.
  • Consent of parent or guardian if less than 18 years of age.

NOTE:

  • Participating centers are encouraged to enroll female patients.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Any grade 3 or greater toxicity.
  • Symptoms of peripheral neuropathy.
  • Malabsorption or severe chronic diarrhea.
  • Inability to eat at least one meal daily because of chronic nausea, emesis, or abdominal or esophageal discomfort.

Concurrent Medication:

Excluded during the first 28 days of nevirapine administration:

  • Augmentin and other antibiotics containing clavulanic acid.

Excluded at any time:

  • Dicumarol, warfarin, and other anticoagulant medications.
  • Tolbutamide.
  • Cimetidine.
  • Erythromycin.

Patients with the following prior conditions are excluded:

  • History of acute or chronic pancreatitis.
  • History of grade 2 or worse peripheral neuropathy from any cause.

Prior Medication:

Excluded:

  • Any prior antiretroviral therapy.

Excluded within 4 weeks prior to study entry:

  • Immunomodulating agents such as systemic corticosteroids, IL-2, alpha-interferon, beta-interferon, or gamma-interferon.
  • Immunotherapeutic vaccines.
  • Cytotoxic chemotherapy.
  • Erythromycin.
  • Dicumarol, Coumadin / warfarin, and other anticoagulant medications.
  • Phenobarbital.
  • Amoxicillin / clavulanate.
  • Ticarcillin / clavulanate.
  • Tolbutamide.
  • Erythromycin.
  • Cimetidine.

Prior Treatment:

Excluded within 4 weeks prior to study entry:

  • Non-local radiation therapy. Current alcohol or illicit drug use that would interfere with ability to comply with study requirements.
Both
13 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00002347
229C, ICC 001
Not Provided
Not Provided
Parexel
Not Provided
Not Provided
NIH AIDS Clinical Trials Information Service
June 1995

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP